- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01264276
Telemedicine Approaches to Evaluating Acute-phase ROP (e-ROP)
The primary objective of this multi-center clinical study is to evaluate the validity, reliability, feasibility, safety and relative cost-effectiveness of a retinopathy of prematurity (ROP) telemedicine evaluation system to detect eyes of at-risk babies who meet referral warranted ROP (RW-ROP) criteria and therefore need a diagnostic evaluation by an ophthalmologist experienced in ROP.
We shall:
- Calculate the accuracy, using sensitivity and specificity, of the system to provide remote evaluations when compared with the findings of a "gold standard" indirect ophthalmoscopic examination performed by a Study-certified ophthalmologist, rigorously trained in ROP diagnostic examinations (validity);
- Determine intra-reader and inter-reader agreement for deciding whether digital images indicate that the eyes of a baby are in need of diagnostic indirect ophthalmoscopy by an ophthalmologist experienced in ROP (reliability);
- Determine whether imaging evaluation can be achieved for each baby (feasibility);
- Examine ocular and systemic complications associated with digital imaging and compared with those associated with diagnostic examinations performed by an ophthalmologist (safety);
- Compare the costs and benefits of adopting a telemedicine retinal imaging system compared to the current cost of indirect ophthalmoscopic examinations (cost-effectiveness).
연구 개요
상태
정황
상세 설명
Eligibility Criteria:
• Babies with birth weights of <1251 grams(g) at selected large clinical centers in the US and Canada.
Procedures:
• Participants will undergo both digital retinal imaging and clinically indicated indirect ophthalmoscopic examinations on the same day. Wide-field digital images (WF-DI) of both eyes will be captured by non-physician Certified ROP Imagers (CRIs) using standardized imaging protocols. The RetCam Shuttle® (Clarity Medical Systems, Pleasanton, CA), a corneal-contact camera that captures wide field (130 degree field of view) retinal images, will be used.
Masking:
• Study-certified Ophthalmologist and Study-certified Imager at the clinical sites will be masked to each other's findings. The Study Clinical Coordinator (SCC) will remain unmasked. SCC will monitor the clinical noteworthy events and report all adverse events to the site Institutional Review Board (IRB), the Project Director at the Office of Study Chair, and to the Data Coordinating Center (DCC). DCC will prepare closed-session Data Monitoring and Oversight Committee (DMOC) reports. The PI at each site will monitor adverse events.
Outcome Measures:
• The primary outcome measure is detection of referral warranted ROP (RW-ROP) on digital images. Retinal images will be graded by Trained Readers using a standardized protocol to identify eyes with RW-ROP. Results of the gradings will be compared to the diagnostic examinations being performed on each child at the same session when images taken. For comparison, images will also be graded by ROP experts (Expert Readers).
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Kentucky
-
Louisville, Kentucky, 미국, 40202
- University of Louisville
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Children's Hospital Boston
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- University of Minnesota
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- Duke University
-
-
Ohio
-
Columbus, Ohio, 미국, 43205
- Nationwide Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- University of Oklahoma
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37232
- Vanderbilt University
-
-
Texas
-
San Antonio, Texas, 미국, 78229
- University of Texas San Antonio
-
-
Utah
-
Salt Lake City, Utah, 미국, 84132
- University of Utah
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 1N4
- University of Calgary
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Babies with birth weighs of <1251g at selected large clinical centers in the US and Canada.
- Admitted to a participating Neonatal Intensive Care Units (NICU) and expected to survive to 28 days.
- Likely to remain in participating NICU for serial ROP exams.
- Transferred to participating NICU for treatment of ROP (regardless of PMA).
- Parents or guardians have provided informed consent for participation in the study.
Exclusion Criteria:
- Failure to obtain informed consent.
- Known ocular anomalies that prevent imaging of the retina.
- Life threatening anomalies (i.e. heart, neurological, etc).
- Admission to participating NICU with ROP that is already regressing or treated.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Detection of Referral Warranted ROP
기간: 6 weeks
|
6 weeks
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Graham E Quinn, MD, MSCE, Children's Hospital of Philadelphia
간행물 및 유용한 링크
일반 간행물
- Wade KC, Ying GS, Baumritter A, Gong A, Kemper AR, Quinn GE; e-ROP Cooperative Group. Factors in Premature Infants Associated With Low Risk of Developing Retinopathy of Prematurity. JAMA Ophthalmol. 2019 Feb 1;137(2):160-166. doi: 10.1001/jamaophthalmol.2018.5520.
- Quinn GE, Ying GS, Repka MX, Siatkowski RM, Hoffman R, Mills MD, Morrison D, Daniel E, Baumritter A, Hildebrand PL, Schron EB, Ells AL, Wade K, Kemper AR. Timely implementation of a retinopathy of prematurity telemedicine system. J AAPOS. 2016 Oct;20(5):425-430.e1. doi: 10.1016/j.jaapos.2016.06.007. Epub 2016 Sep 17.
- Morrison D, Bothun ED, Ying GS, Daniel E, Baumritter A, Quinn G; e-ROP Cooperative Group. Impact of number and quality of retinal images in a telemedicine screening program for ROP: results from the e-ROP study. J AAPOS. 2016 Dec;20(6):481-485. doi: 10.1016/j.jaapos.2016.08.004. Epub 2016 Oct 1.
- Kemper AR, Prosser LA, Wade KC, Repka MX, Ying GS, Baumritter A, Quinn GE; e-ROP Study Cooperative Group. A Comparison of Strategies for Retinopathy of Prematurity Detection. Pediatrics. 2016 Jan;137(1):e20152256. doi: 10.1542/peds.2015-2256. Epub 2015 Dec 15.
- Wade KC, Pistilli M, Baumritter A, Karp K, Gong A, Kemper AR, Ying GS, Quinn G; e-Retinopathy of Prematurity Study Cooperative Group. Safety of Retinopathy of Prematurity Examination and Imaging in Premature Infants. J Pediatr. 2015 Nov;167(5):994-1000.e2. doi: 10.1016/j.jpeds.2015.07.050. Epub 2015 Aug 20.
- Kemper AR, Wade KC, Hornik CP, Ying GS, Baumritter A, Quinn GE; Telemedicine Approaches to Evaluating Acute-phase Retinopathy of Prematurity (e-ROP) Study Cooperative Group. Retinopathy of prematurity risk prediction for infants with birth weight less than 1251 grams. J Pediatr. 2015 Feb;166(2):257-61.e2. doi: 10.1016/j.jpeds.2014.09.069. Epub 2014 Nov 12.
- Quinn GE, Ying GS, Daniel E, Hildebrand PL, Ells A, Baumritter A, Kemper AR, Schron EB, Wade K; e-ROP Cooperative Group. Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity. JAMA Ophthalmol. 2014 Oct;132(10):1178-84. doi: 10.1001/jamaophthalmol.2014.1604.
- Graham E Quinn; e-ROP Cooperative Group. Telemedicine approaches to evaluating acute-phase retinopathy of prematurity: study design. Ophthalmic Epidemiol. 2014 Aug;21(4):256-67. doi: 10.3109/09286586.2014.926940. Epub 2014 Jun 23.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
미숙아 망막병증에 대한 임상 시험
-
Queens College, The City University of New York모병
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)완전한
-
Hôpital Léon Bérard완전한
-
Swansea University완전한A Bite of ACT' (BOA) 수용전념치료 온라인 심리교육 과정 | 대기자 명단 제어영국
-
Scripps Translational Science Institute완전한
-
Novartis Pharmaceuticals완전한신경내분비종양 | GI 오리진의 고급 NET | 고급 NET of Lung Origin미국, 콜롬비아, 이탈리아, 대만, 영국, 벨기에, 체코, 독일, 일본, 사우디 아라비아, 캐나다, 네덜란드, 스페인, 대한민국, 레바논, 오스트리아, 중국, 그리스, 남아프리카, 태국, 헝가리, 칠면조, 폴란드, 슬로바키아, 러시아 연방
-
University Hospital Inselspital, BerneDeka Medical, Inc.모집하지 않고 적극적으로
-
Peking Union Medical College Hospital아직 모집하지 않음효능 및 안전성 | 과민성 대장 증후군 - 설사 | N of 1 연구 설계 | 한의학(TCM)중국
-
Catherine Vandepitte, M.D.Pacira Pharmaceuticals, Inc완전한
-
University of Pennsylvania완전한Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410의 주진단 또는 이차진단 코드가 있는 환자(5번째 숫자가 2인 경우 제외)미국